That's a good list.
Some more inadequate planning ones:
* insufficiently powered
* inefficient ratio of sample sizes in treatment arm and control arm
* wrong treatment in control arm, e.g wrong interpretation of Standard of Care
* failing to recruit clinicians in an acceptable timeframe
Getting patient selection criteria wrong can be either wrong inclusion criteria or wrong exclusion criteria or both.
There are many opportunities to stuff up.
(II thinks: What am I doing in this stock?)
Pillar 2 - Breast Cancer, page-90
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $265.8M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3015 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 4018 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |